Wide Ranks

DBVT

DBV Technologies S.A.

0.6130

Top Statistics
Market Cap 58 M Forward PE -0.6081 Revenue Growth -54.80 %
Current Ratio 2.22 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA Enterprise / Revenue 1.61 Price To Sales Trailing12 Months 4.71
Profitability
Profit Margins 0.00 % Operating Margins -2829.20 %
Balance Sheet
Total Cash 46 M Total Cash Per Share 0.4810 Total Debt 7 M
Total Debt To Equity 13.72 Current Ratio 2.22 Book Value Per Share 0.5620
All Measures
Short Ratio 74.00 % Message Board Id finmb_7406282 Fax 33 1 43 26 10 83
Shares Short Prior Month 67000 Return On Equity -1.03 City Montrouge
Uuid 743365e9-cced-3e92-b167-5177b9f2dfd9 Previous Close 0.6060 First Trade Date Epoch Utc 1 B
Book Value 0.5620 Beta 0.8640 Total Debt 7 M
Volume 327487 Price To Book 1.09 Last Split Date 1 B
Fifty Two Week Low 0.5400 Total Cash Per Share 0.4810 Total Revenue 12 M
Shares Short Previous Month Date 1 B Target Median Price 5.48 Max Age 86400
Sand P52 Week Change 0.3133 Operating Margins -2829.20 % Target Mean Price 5.48
Net Income To Common -102089000 Short Percent Of Float 0.0033 Implied Shares Outstanding 108 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 25848
Average Volume10days 25848 Total Cash 46 M Next Fiscal Year End 1 B
Revenue Per Share 0.1300 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 0.6060 Target Low Price 4.49
Gmt Off Set Milliseconds -18000000 Fifty Day Average 3.42 Open 0.6299
Free Cashflow -75982624 Dividend Yield 0.00 % Return On Assets -0.4625
Time Zone Short Name EST Trailing Eps -5.30 Day Low 0.5400
Address1 177-181 Avenue Pierre Brossolette Shares Outstanding 96 M Price Hint 4
Target High Price 6.47 Website https://www.dbv-technologies.com 52 Week Change -0.5858
Average Volume 137076 Forward Eps -1.07 Recommendation Key none
Compensation As Of Epoch Date 1 B Quick Ratio 215.30 % Last Split Factor 1:5
Regular Market Day High 0.6299 Is_sp_500 False Profit Margins 0.00 %
Debt To Equity 13.72 Fifty Two Week High 10.70 Day High 0.6299
Shares Short 251296 Regular Market Open 0.6299 Industry Key biotechnology
Earnings Growth 0.00 % Enterprise To Revenue 1.61 Revenue Growth -54.80 %
Shares Percent Shares Out 0.0026 Operating Cashflow -105908000 Currency USD
Time Zone Full Name America/New_York Market Cap 58 M Is_nasdaq_100 False
Zip 92120 Quote Type EQUITY Industry Biotechnology
Long Name DBV Technologies S.A. Regular Market Day Low 0.5400 Held Percent Institutions 0.1673
Current Price 0.6130 Financial Currency USD Current Ratio 2.22
Gross Margins 100.00 % Industry Disp Biotechnology Number Of Analyst Opinions 2
Country France Float Shares 41 M Two Hundred Day Average 5.19
Enterprise Value 20 M Price To Sales Trailing12 Months 4.71 Forward PE -0.6081
Regular Market Volume 327487 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
DBV Technologies S.

A.

, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products.

Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.

The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes.

In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy.

The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers.

DBV Technologies S.

A.

was incorporated in 2002 and is headquartered in Montrouge, France.